Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
like a rocket FBC goes from 1.50 to 1.84...I originally had a limit order at 1.69 but cancelled it and sold for 1.50 earlier....that has been the way of my last few trades...sold tooooo soon....ucbi comes to mind.....
exited fbc at 1.50 entered 1.25 for 20% gainer
R.I.P.
looking at the chart it seems like blue sky up to 1.70 but was looking for end of day run to possibly sell as the overall markets look to be getting to pricey
FBC HOD 1.51
thanks for the link.
thanks for that explanation :)
me too got an order in at 4.90...still holding FBC, HOTT and DVOX
fbc on the move....over 1.42 finally....target 1.70
ppc up another 6% today....I thought 7.35 was good....
anyone playing this?
boardmarked
exited at 7.35 took a 10+ gainer
boardmarked
ppc had a great day.....possible sale on a morning pop...
better than me....glt us
Bernstein Liebhard LLP Announces Investigation of Geron Corporation
Geron (MM) (NASDAQ:GERN)
Intraday Stock Chart
Today : Thursday 9 December 2010
Bernstein Liebhard LLP has commenced an investigation into possible violations of the law by certain officers and directors of Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN).
The investigation focuses on allegations that certain statements made by the Company concerning Geron’s business and operations were materially false and/or misleading.
On October 29, 2010, Geron CFO David Greenwood stated in a conference call that the Company was ending the third quarter with $146 million cash on the balance sheet. Greenwood also stated that Geron was “funded for the near-term.” Greenwood had said the same thing about funding on July 30, 2010 at the end of the second quarter, when he reported $156 million cash on the balance sheet.
Yet, on December 6, 2010, only five weeks after the October conference call, Geron surprised investors by announcing an $87 million secondary public offering (“SPO”) of 17.4 million shares. Further, the SPO was priced at $5 per share – when Geron was trading at $6.12 at the time. After the announcement of the SPO – contradicting Greenwood’s earlier statements that the Company was funded for the near-term – shares of the Company fell about 20% on December 7, 2010.
If you are interested in discussing your rights as a Geron shareholder and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.
Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered almost $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last eight years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com
ppc having a strong day in a weak market
still holding dvox....thoughts?
what's up with the digster?
order in at 4.60 but did not get filled
trying to get back in down at .25
still holding HOTT, FBC, PPC and DVOX
just wondering, when you are selected to assist do you get paid?
nice day....I am very pleased for all the longs who have been here a while...have a nice weekend
anyone feeling less hot about hott?
fbc on the move too
ucbi tearing it up again
PPC looking great technically trading above 8/20/50 dmas lots room overhead
out of ucbi with 16% gain at 1.68 but unfortunately not a huge amount of shares.
finally got a complete fill 1000@ 4.08 on DVOX
ucbi and ppc looking good....unfortunately I took mylimit order off on ucbi to buy at 1.45 after only getting a partial fill initally
Here are pieces of the email alert I received...It was from Caldwell
ACTC Secures History-Making FDA Approval, Sharpens Focus on $25B Market for Dry AMD
New This Week
Dear Investors:
I am proud to share the news that the little biotech company I run, Advanced Cell Technology, Inc. (OTCBB: ACTC) has just made history by receiving approval for the first-ever human clinical trial using embryonic stem cells to treat eye disease (see a slew of top-tier press coverage here).
Focused on a form of Macular Degeneration called Stargardt's Disease, this clinical trial will dovetail nicely with another that we are preparing for, using the same proprietary technology platform, for Dry Age-Related Macular Degeneration (AMD). We plan to file an Investigational New Drug Application (IND) with the FDA for our "Dry AMD" program within weeks.
The market for Dry AMD is between $25-30 Billion in the US and Europe alone, and there are currently no effective therapies available for it.
BARRON'S Online: ACTC a "Strong Buy!"
"Mean Recommendation" of 1 ("Strong Buy") on BARRON'S
"Company Research" Page on ACTC
Human embryonic stem cells (hESCs) are the body's master cells, capable of becoming any cell in the human body. Our field, called "Regenerative Medicine," aims to harness these cells, and has the potential to revolutionize medicine, potentially proving cures for a variety of debilitating diseases and conditions, including Macular Degeneration, Heart Disease, Parkinson's Disease, Diabetes, spinal cord injuries, and many more, and saving hundreds of billions - even trillions - of dollars in healthcare expenditures worldwide.
Sad to say, over the last decade the field has been plagued with hype from some quarters, as well as political setbacks. Now, however, with this FDA approval, stem cell research is now about to "get real," with ACTC as a lead player.
Click here for the BBC's streaming interview last week with our Chief Scientific Officer, Dr. Robert Lanza
I took the helm of ACTC in 2005, coming from a diverse business background, having ushered a variety of companies through growth stages as well as steering them through successful dealings with an alphabet soup of regulatory agencies. I also spent years as an investment banker, so you might say I have a better nose for a good investment than many CEOs.
ACTC has a novel, proprietary method of deriving hESCs without damage to the embryo. As a result of this "single-cell blastomere" technique,ACT may be uniquely positioned as one of the few sources of hESCs that could qualify for federal funding under the recent federal court ruling.
Click here for TIME Magazine's coverage of our FDA Approval on November 22.
ACTC stock has recently been trading in the $.04-.07 range, and the 52-week range is $.04-.12. As of this writing, the three-month average trading volume was over Five Million shares.
On Bloomberg TV
I encourage you to peruse some of the media coverage linked to here, as well as our company website at http://www.advancedcell.com/.
We are confident that this history-making development will propel us into a new phase in our growth as a company.
Click here for coverage from "The Newspaper of Record."
If you have any questions or comments about the company or the stock, feel free to post them to my official Chairman's blog. I will do my best to address your queries and comments.
Please also follow our official company blogs, accessible through the company's front page.
I got an email from sec.filings this AM promoting actc...mentions Baron's online gives strong buy and something about cnbc powerlunch
think I will get me 1000 shares.....
rub it in.....i got a measly 3.5% return....nice trade
just got some .065s...lets start up again
Net loss from continued operations for the nine month period ended September 30, 2010 totaled $7.8 million or $(0.12) per share based on 65.7 million shares outstanding compared to a net loss of approximately $12.6 million or $(1.21) per share based on 10.46 million shares outstanding.
How many shares authorized?
got a partial fill on UCBI this AM 500 @ 1.45 the other 1500 did not fill....sold APP too early